HumeCare+ review
The rate is stated to hold at every dose, and what it covers includes a physical device as well as the medication.
The verdict
HumeCare+ publishes a flat $199 a month for compounded semaglutide by injection and states that the figure holds at every dose, while its pill and tirzepatide lines are priced only after an assessment. The semaglutide figure covers the medication, the provider consultation and a device the company calls the Hume Pod, against an anchor price of $299 that nobody appears to pay.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- From
- From $199/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- 47 states, list published
HumeCare+ sells semaglutide as a once-weekly injection or a pill and tirzepatide by injection only, with the tirzepatide line sold exclusively as a B12 and glycine combination rather than as plain tirzepatide. Only the injection carries a published figure, shown against a higher anchor number; the company's own comparison pages describe the other two as not published until an assessment.
Who writes the prescription, and what do they see?
The provider consultation sits inside the monthly figure rather than beside it, so the clinical relationship is not a separate charge a buyer discovers later. What the pages do not describe is how often that consultation happens or what a prescriber reviews before writing, which is the same gap almost every seller in this category leaves.
Two things here are worth more than the price. The first is the flat-rate statement, made explicitly at every dose rather than left to be discovered during a titration. The second is the inclusion list, which extends past medication and consultation to a physical device. That is an unusual thing to fold into a monthly rate, and it makes the figure harder to compare against a plain medication price elsewhere.
What happens when the dose goes up?
HumeCare+ states plainly that the rate is flat at every dose. That is among the most useful sentences a seller in this category can publish. Escalation across the first sixteen weeks is the normal path, and a rate that moves at each step costs more over a year than any gap between competitors. What the pages do not state is the milligram range the flat rate covers.
What the price includes
The anchor prices are the part to treat carefully. Semaglutide is presented at $199 against a $299 anchor, and nothing on the pages suggests the higher figure is ever charged. An anchor nobody pays is a framing device rather than a price. What gives the real figures their weight is the flat-rate statement beside them: $199 a month that genuinely holds through a titration is a different proposition from $199 that resets at every step.
What it claims, and what it cites
All three lines are compounded, which places them outside the FDA review an approved product completes before dispensing. The tirzepatide is available only as a combination with B12 and glycine, with no plain line offered. A buyer wanting the molecule alone cannot get it here, and the pages do not explain why the combination is the only option.
Where it holds up, and where it does not
- Strength: Flat rate stated explicitly at every dose
- Strength: Consultation sits inside the figure
- Strength: A device is included rather than sold apart
- Strength: The injection price is published before an assessment
- Limitation: Tirzepatide comes only as a combination
- Limitation: The anchor price appears to be nominal
- Limitation: The pill and tirzepatide are priced only after an assessment
- Limitation: No milligram range is published
- Limitation: No state coverage list is recorded
What the evidence says about this kind of treatment
The assessment above is about HumeCare+. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who wants the rate pinned across a titration and the consultation counted in.
- Wrong for
- A reader who wants tirzepatide on its own rather than as a combination product.
The evidence behind what HumeCare+ prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How HumeCare+ compares
| Seller | Who it suits | Go |
|---|---|---|
| EverSlim | A reader who wants one monthly charge covering the medication, the visit and the postage, without a prepay term attached to reach the rate. | See EverSlim → |
 Idgie Health | A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. | See Idgie Health → |
| Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | See Bayan Health → |
More GLP-1 telehealth sellers reviews: CurexDadVantage Men's HealthDoctorAdamDollar Dad ClubDr. ArevitalizeDr. Gillis' Wellness Center
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Does the price really hold at every dose?
- HumeCare+ states it does. That is worth confirming at intake, because it is the claim that decides what a year costs.
- What is the Hume Pod?
- A device the company includes in the monthly figure alongside the medication and the provider consultation. The pages do not price it separately.
- Can I get tirzepatide without the additives?
- Not here. The tirzepatide line is sold only as a B12 and glycine combination, with no plain version offered and no explanation given.
- Is HumeCare+ expensive compared with other GLP-1 telehealth sellers?
- HumeCare+ publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts HumeCare+ above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.